IMMUNE DESIGN CORP. (NASDAQ:IMDZ) Files An 8-K Financial Statements and ExhibitsItem 9.01.
Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description |
|
99.1 |
Press Release, dated October 11, 2018.
|
IMMUNE DESIGN CORP. ExhibitEX-99.1 2 exhibit991oct11press.htm EXHIBIT 99.1 Exhibit Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305 •G100 development to accelerate in follicular lymphoma and beyond•CMB305 to be deprioritized to support focus on G100•Cash runway extended into 2021•Conference call at 2:00 pm Pacific todaySEATTLE and SOUTH SAN FRANCISCO,…To view the full exhibit click here
About IMMUNE DESIGN CORP. (NASDAQ:IMDZ)
Immune Design Corp. is a clinical stage immunotherapy company. The Company focuses on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its discovery platforms, including ZVex and GLAAS. ZVex is a discovery platform that uses a vector to generate product candidates designed to create cytotoxic T cells (CTLs) in vivo. The ZVex vector is a delivery system based on a hybrid, re-engineered virus designed to carry the genetic information of selected tumor antigen in whole or selected epitopes selectively to dendritic cells (DCs) in the skin. When injected into a cancer patient, a ZVex-based product candidate is designed to interact only with these DCs, delivering the tumor antigen in the form of ribonucleic acid (RNA). GLA Adjuvant Systems (GLAAS) is a discovery platform that works in vivo and is based on a synthetic molecule called glucopyranosyl lipid A (GLA).